J&J Keeps Its Patent Protection On Topamax

  • October 25, 2006
Johnson & Johnson's Ortho-McNeil Neurologics said a U.S. District Court has granted its request for a preliminary injunction to stop Mylan Laboratories Inc. from launching a generic version of Topamax before the final court decision on the validity of the patent. The patent for Topamax, an anti-epileptic drug, expires September 2008. Ortho-McNeil said a trial date hasn't yet been set.

Next story loading loading..